FORALUMAB



NAME OF DRUG : FORALUMAB

ALSO KNOWN AS : FORALUMAB

LABORATORY : TIZIANA

STATUS AND ADVANCEMENT

Type of drug : anti-CD3 monoclonal antibody (mAbs)

Clinical trials advancement : Initiating Phase 2a

Estimated time to market : 122 months.

LABORATORY ABSTRACT ON THE DRUG

Foralumab (TZLS-401) has significant potential as the only fully human engineered anti-human CD3 antibody in clinical development with advantages of short duration of treatment regimen and reduced immunogenicity.

With Phase II development for Crohn’s Disease completed, modulation of T-cell response provides potential extension into a wide range of other autoimmune and inflammatory diseases, such as NASH, PBC, ulcerative colitis, multiple sclerosis and autoimmune Type-1 diabetes. Foralumab is being developed as both an immunosuppressive and immunomodulatory agent, with therapeutic benefits of rendering T-cells unable to orchestrate an immune response and induction of immune tolerance via maintenance of regulatory T-cells.

RECENT NEWS ON FORALUMAB

2017-09-06 : Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH

SOME PUBLICATIONS RELATED WITH FORALUMAB

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH FORALUMAB


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE